JP6744856B2 - α−シヌクレインを認識する抗体を含む血液脳関門シャトル - Google Patents

α−シヌクレインを認識する抗体を含む血液脳関門シャトル Download PDF

Info

Publication number
JP6744856B2
JP6744856B2 JP2017504288A JP2017504288A JP6744856B2 JP 6744856 B2 JP6744856 B2 JP 6744856B2 JP 2017504288 A JP2017504288 A JP 2017504288A JP 2017504288 A JP2017504288 A JP 2017504288A JP 6744856 B2 JP6744856 B2 JP 6744856B2
Authority
JP
Japan
Prior art keywords
blood
antibody
seq
brain barrier
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514515A5 (enExample
JP2017514515A (ja
Inventor
ロビン・バーバー
ケイト・ドーラ・ゲイムス−シール
ターロチャン・エス・ニイジャー
ワグナー・ザーゴ
オラフ・ムンディグル
イェンス・ニーヴェーナー
ゲオルグ・ティーフェンターラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2017514515A publication Critical patent/JP2017514515A/ja
Publication of JP2017514515A5 publication Critical patent/JP2017514515A5/ja
Application granted granted Critical
Publication of JP6744856B2 publication Critical patent/JP6744856B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
JP2017504288A 2014-04-08 2015-04-08 α−シヌクレインを認識する抗体を含む血液脳関門シャトル Active JP6744856B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461977042P 2014-04-08 2014-04-08
US201461977039P 2014-04-08 2014-04-08
US61/977,039 2014-04-08
US61/977,042 2014-04-08
US201462023373P 2014-07-11 2014-07-11
US62/023,373 2014-07-11
PCT/IB2015/052524 WO2015155694A1 (en) 2014-04-08 2015-04-08 Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020130589A Division JP2020195382A (ja) 2014-04-08 2020-07-31 α−シヌクレインを認識する抗体を含む血液脳関門シャトル

Publications (3)

Publication Number Publication Date
JP2017514515A JP2017514515A (ja) 2017-06-08
JP2017514515A5 JP2017514515A5 (enExample) 2018-05-10
JP6744856B2 true JP6744856B2 (ja) 2020-08-19

Family

ID=53052905

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017504288A Active JP6744856B2 (ja) 2014-04-08 2015-04-08 α−シヌクレインを認識する抗体を含む血液脳関門シャトル
JP2020130589A Pending JP2020195382A (ja) 2014-04-08 2020-07-31 α−シヌクレインを認識する抗体を含む血液脳関門シャトル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020130589A Pending JP2020195382A (ja) 2014-04-08 2020-07-31 α−シヌクレインを認識する抗体を含む血液脳関門シャトル

Country Status (5)

Country Link
US (2) US10562973B2 (enExample)
EP (1) EP3129051A1 (enExample)
JP (2) JP6744856B2 (enExample)
CA (1) CA2944402A1 (enExample)
WO (1) WO2015155694A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3378535T (lt) 2011-10-28 2023-02-27 Prothena Biosciences Limited Humanizuoti antikūnai, atpažįstantys alfa-sinukleiną
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA3028035A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
BR112020011875A2 (pt) * 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
US11753455B2 (en) * 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity
AU2019320803A1 (en) * 2018-08-16 2021-03-11 Denali Therapeutics Inc. Engineered bispecific proteins
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
CA3135181A1 (en) * 2019-04-05 2020-10-08 B-Portal Biologics, Inc. Fusion constructs and uses thereof
WO2020223310A2 (en) * 2019-04-29 2020-11-05 Thomas Jefferson University Methods for treating neurodegenerative disorders
CA3186614A1 (en) 2020-07-23 2022-01-27 Michael SKOV Anti-abeta antibodies
IL301262A (en) * 2020-09-18 2023-05-01 Othair Prothena Ltd Multiepitope vaccine for the treatment of alzheimer's disease
WO2025054419A1 (en) * 2023-09-08 2025-03-13 California Institute Of Technology Compositions for transport of therapeutic cargos using antibody binders targeting ca-iv

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1575961A (en) 1977-09-07 1980-10-01 Sekisui Chemical Co Ltd Foamable compositions and their use in preparing foams
DE3133101A1 (de) 1981-08-21 1983-03-10 Hoechst Ag, 6000 Frankfurt Verfahren zur entfernung von katalysatorresten aus polyolefinen
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
KR0163798B1 (ko) 1991-07-03 1999-01-15 나가따 마사오 열가성 폴리우레탄 탄성체, 그의 제조 방법, 그의 제조 장치 및 그로부터 제조한 탄성 섬유
US5209485A (en) 1991-09-23 1993-05-11 Lisco, Inc. Restricted flight golf ball
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5208362A (en) 1992-02-27 1993-05-04 Ethyl Corporation Process for stabilizing organophosphorus compounds
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100405399C (zh) 1999-02-05 2008-07-23 三星电子株式会社 图像纹理恢复方法及其装置
ES2312348T3 (es) 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
WO2002034824A2 (en) 2000-10-23 2002-05-02 Dow Global Technologies Inc. Propylene polymer foams
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6583190B2 (en) 2000-12-27 2003-06-24 Sealed Air Corporation (U.S.) Expandable composition, blowing agent, and process for extruded thermoplastic foams
KR100456392B1 (ko) 2001-02-01 2004-11-10 미쓰이 가가쿠 가부시키가이샤 올레핀계 엘라스토머 가교발포체용 엘라스토머 조성물 및그의 용도
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
EP1531864A4 (en) 2002-05-13 2006-08-23 Alexion Pharma Inc HUMANIZED ANTIBODIES TO THE VENEZOLAN HORSEMEN ENZEPHALITIS VIRUS
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2006089637A (ja) 2004-09-24 2006-04-06 Kaneka Corp ポリプロピレン系樹脂発泡シートの製造方法
DK1820022T3 (da) 2004-11-10 2009-09-14 Boehringer Ingelheim Pharma Anvendelse af flow-cytometrisk analyse for at optimere cellebanks-strategier af CHO-celler
US7179873B2 (en) 2005-01-26 2007-02-20 Fina Technology, Inc. Branched ionomers
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
AU2006326301B2 (en) 2005-12-12 2011-04-21 F. Hoffmann-La Roche Ag Antibodies against amyloid beta 4 with glycosylated in the variable region
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2118300B1 (en) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
DK2126093T3 (da) 2007-03-02 2013-01-07 Boehringer Ingelheim Pharma Forbedring af proteinfremstilling
UA96473C2 (ru) 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
TWI464178B (zh) 2007-03-22 2014-12-11 Genentech Inc 細胞凋亡抗-ｉｇｅ抗體
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP2237803B1 (en) 2007-12-28 2015-07-01 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
EP2260112A4 (en) 2008-04-05 2013-10-09 Single Cell Technology Inc SCREENING PROCESS FOR INDIVIDUAL CELLS FOR THE MANUFACTURE OF BIOLOGICAL ACTIVE SUBSTANCES
TR201901497T4 (tr) 2008-04-29 2019-02-21 Bioarctic Ab Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar.
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
DE102008048129A1 (de) 2008-09-20 2010-04-22 Lfk-Lenkflugkörpersysteme Gmbh Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper
RU2011116112A (ru) 2008-09-26 2012-11-10 Роше Гликарт Аг (Ch) Биспецифические анти-egfr/анти-igf-1r антитела
RU2011117213A (ru) 2008-09-30 2012-11-10 Эббот Лэборетриз (Us) Улучшенные библиотеки антител
EP3699296A1 (en) 2008-11-07 2020-08-26 Adaptive Biotechnologies Corporation Methods of monitoring conditions by sequence analysis
NZ593964A (en) 2008-12-19 2012-12-21 Univ Zuerich Human anti-alpha-synuclein autoantibodies
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
US20110053803A1 (en) 2009-08-26 2011-03-03 Xin Ge Methods for creating antibody libraries
EP2519537A4 (en) 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
LT2646470T (lt) 2010-11-30 2017-06-12 F. Hoffmann-La Roche Ag Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
US8741298B2 (en) 2011-02-07 2014-06-03 Neotope Biosciences Limited APOE immunotherapy
US20120220730A1 (en) 2011-02-24 2012-08-30 Fina Technology, Inc. High Melt Strength Polypropylene and Methods of Making Same
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
US8715449B2 (en) 2011-06-17 2014-05-06 Berry Plastics Corporation Process for forming an insulated container having artwork
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
US9045615B2 (en) 2011-08-24 2015-06-02 Fina Technology, Inc. Metal carboxylate additives for thermoplastics
US20130063945A1 (en) 2011-09-12 2013-03-14 Chaun-Choung Technology Corp. Bulb-type led lamp having replaceable light source module
LT3378535T (lt) 2011-10-28 2023-02-27 Prothena Biosciences Limited Humanizuoti antikūnai, atpažįstantys alfa-sinukleiną
AU2012332767C1 (en) 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
US8829114B2 (en) 2011-11-29 2014-09-09 Fina Technology, Inc. Preparation of metallic comonomers for polystyrene
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
HRP20191153T1 (hr) 2012-08-29 2019-10-04 F. Hoffmann - La Roche Ag Prijenosnik za krvno-moždanu barijeru
US8925815B2 (en) 2012-09-05 2015-01-06 Symbol Technologies, Inc. Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods

Also Published As

Publication number Publication date
US20200299397A1 (en) 2020-09-24
JP2020195382A (ja) 2020-12-10
CA2944402A1 (en) 2015-10-15
US20170174777A1 (en) 2017-06-22
JP2017514515A (ja) 2017-06-08
WO2015155694A1 (en) 2015-10-15
US10562973B2 (en) 2020-02-18
EP3129051A1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
US10875910B2 (en) Antibodies recognizing alpha-synuclein
JP6744856B2 (ja) α−シヌクレインを認識する抗体を含む血液脳関門シャトル
AU2016202622B2 (en) Humanized antibodies that recognize alpha-synuclein
JP6807893B2 (ja) α−シヌクレインを認識するヒト化抗体
HK1212361B (en) Antibodies recognizing alpha-synuclein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200731

R150 Certificate of patent or registration of utility model

Ref document number: 6744856

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250